A Phase 1 Study of TJ011133 Administered Alone or in Combination with
Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Other exclusion criteria may apply.